The Center for the Study of Inflammatory Bowel Disease (CSIBD) is a multidisciplinary program to define fundamental mechanisms underlying Crohn's disease and Ulcerative colitis. This Center encompasses one hundred and one investigators at the Massachusetts General Hospital (MGH) and allied institutions pursuing research in a broad spectrum of basic science relevant to IBD. Since its formation nineteen years ago, the CSIBD has served as a vehicle to achieve advances in our understanding of these diseases through the study of relevant basic biological processes and the directed study of the diseases themselves. The research program of this Center is organized around the central hypothesis that IBD results from activation by luminal bacteria or their products of an upregulated chronic immune response due to genetically determined alterations of epithelial cell or immune function including a lack of appropriate down regulatory functions. Major advances made possible by the CSIBD in the years since its inception include the development and characterization of new genetic mouse models of IBD, delineation of mechanisms of lymphocyte activation and leukocyte recruitment to sites of inflammation, characterization of mechanisms of innate immune response, identification of key peptides involved in sustaining mucosal integrity, characterization of the mechanisms of mucosal healing following injury, improved understanding of the regulation of epithelial function, functional mapping of genetic variants in IBD, mucosal immune responses and delineation of the mechanisms of mucosal microbial interaction. Over the next five years, the CSIBD will promote further progress in the study of basic aspects of mucosal biology with translation to the study and treatment of IBD. A major focus of CSIBD research in the next five years will be the coordinated multi-disciplinary study of mechanisms leading to chronic intestinal inflammation and delineation of interactions between environmental factors and different genetic loci. The Center will also actively promote clinical and translational research efforts to apply insights gained in studying various disease mechanisms. The overall goal of advancing our knowledge of IBD will continue to be carried out through five Biomedical Cores. These include Genetic analysis, Genomics and Molecular Biology (GGMB), Morphology and Immunology Cores to provide access to advanced technologies. The Genetic Animal Models and Human Cell/Tissue Cores provide access to relevant animal models and patients for study. In the coming period facilitated access for CSIBD investigators to several platforms of the Broad institute has been arranged. CSIBD cores are heavily oriented towards hands on training. In addition to advancing the understanding of IBD per se, the goals of this Center will continue to include the recruitment of investigators committed to pursuing IBD research. These goals are fostered by Pilot/Feasibility Study awards which support new research initiatives as well as an enrichment program of seminars, workshops and symposia.
The center provides high quality, cutting edge and technical support to investigators performing inflammatory bowel disease related research. It also provides pilot feasibility grants for IBD related research, a resource that has been avidly sought by area investigators.
|Gevers, Dirk; Kugathasan, Subra; Knights, Dan et al. (2017) A Microbiome Foundation for the Study of Crohn's Disease. Cell Host Microbe 21:301-304|
|Molinie, Benoit; Giallourakis, Cosmas C (2017) Genome-Wide Location Analyses of N6-Methyladenosine Modifications (m6A-Seq). Methods Mol Biol 1562:45-53|
|Schwerd, Tobias; Pandey, Sumeet; Yang, Huei-Ting et al. (2017) Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. Gut 66:1060-1073|
|Maehara, Takashi; Mattoo, Hamid; Ohta, Miho et al. (2017) Lesional CD4+ IFN-?+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann Rheum Dis 76:377-385|
|Jung, Keehoon; Heishi, Takahiro; Khan, Omar F et al. (2017) Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest 127:3039-3051|
|Rooks, Michelle G; Veiga, Patrick; Reeves, Analise Z et al. (2017) QseC inhibition as an antivirulence approach for colitis-associated bacteria. Proc Natl Acad Sci U S A 114:142-147|
|Ananthakrishnan, Ashwin N; Luo, Chengwei; Yajnik, Vijay et al. (2017) Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe 21:603-610.e3|
|Canali, Susanna; Zumbrennen-Bullough, Kimberly B; Core, Amanda B et al. (2017) Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 129:405-414|
|Ananthakrishnan, A N; Sakuraba, A; Barnes, E L et al. (2017) The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther 46:162-168|
|Miyabe, Chie; Miyabe, Yoshishige; Strle, Klemen et al. (2017) An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis 76:898-905|
Showing the most recent 10 out of 1056 publications